Drug Profile
Levodopa deuterated - Teva Pharmaceutical Industries
Alternative Names: Deuterium containing levodopa - Teva Pharmaceutical Industries; Deuterium substituted levodopa - Teva Pharmaceutical Industries; SD-1077Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Imphar AG
- Developer Teva Pharmaceutical Industries
- Class Antiparkinsonians; Catecholamines; Organic deuterium compounds; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 05 May 2015 Auspex Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
- 16 Mar 2015 Auspex Pharmaceuticals has patent protection for levodopa deuterated in USA and European Union (Auspex Pharmaceuticals 10-K, March 2015)